ALS Hits Record $381M Profit and Clears FY27 Targets a Full Year Early

ALS delivers record earnings in FY26, beating its own targets a year early

In its FY26 full year results presentation, ALS Limited CEO and Managing Director Malcolm Deane and CFO Stuart Hutton outlined a milestone year for the global testing, inspection and certification group, with revenue rising 10.7% to $3.32 billion and underlying net profit after tax (NPAT) climbing 25.8% to a record $381.2 million. The presentation’s headline achievement was the early delivery of FY27 financial targets, completed a full year ahead of schedule. Management attributed the result to strong execution across both the Commodities and Life Sciences portfolios, with the group’s underlying EBIT margin expanding 129 basis points (bps) to 18.0% and a full year dividend of 42.5 cents per share (cps), up 10.1%, representing a 57% payout ratio of underlying NPAT.

FY26 by the numbers — a clean sweep across revenue, earnings and returns

The presentation detailed a comprehensive set of financial improvements across every major metric, from earnings to returns on capital.

The balance sheet position strengthened considerably over the year. Net debt fell from $1,424.1 million to $1,069.5 million, with leverage at 1.5x sitting below the lower bound of the group’s targeted 1.7x–2.3x range. Group liquidity exceeded $580 million. The primary driver of deleveraging was the equity raise of approximately $367 million completed in H1 FY26, which also reinforced the group’s capacity to pursue both organic hub lab investment and bolt-on acquisitions.

Commodities leads the charge with Minerals margin at 33%

The Commodities division was the standout performer in FY26. Revenue grew 18.8% to $1,294.2 million (18.1% at constant currency), representing 39% of group revenue, with underlying EBIT margin expanding 167 bps to 29.5%. Within Commodities, the Minerals segment was particularly strong, with margin expanding 250 bps to 33.0%, driven by a combination of volume growth, pricing uplift and operating leverage.

Geochemistry delivered organic revenue growth of 22.7%, reflecting improved sample volumes from exploration testing and continued uptake of mine site production testing. Metallurgy posted a full-year organic decline of (2.5%), though the presentation highlighted a return to positive organic growth in H2, with a healthy and well-diversified forward pipeline. Junior financing more than doubled year-on-year, and H2 saw the first uptick in junior sample volumes in recent periods, a recovery signal management noted with cautious optimism.

Industrial Materials posted +10.5% organic growth across the segment, with the key sub-segments performing as follows:

• Oil & Lubricants: +12.2% organic growth (margin compressed due to greenfield expansion investment)
• Assay & Inspection: +11.4% organic growth (margin expanded through pricing and mix improvement)
• Coal: +7.6% organic growth (margin compressed due to sale and leaseback occupancy costs)

Life Sciences — core strength intact despite mixed regional outcomes

Life Sciences generated revenue of $2,025.9 million, up 6.0% (3.4% at constant currency), contributing 35% Environmental and 26% Pharmaceutical to group revenue. The division’s underlying EBIT margin improved 55 bps to 14.6%, with the core margin excluding Nuvisan, Wessling and York at 16.8%, up 32 bps.

Food delivered its third consecutive year of strong organic growth at 7.2%, with Europe the standout region and organic EBIT margin expanding 120 bps through process and efficiency improvements. Environmental grew 2.8% organically, with EMEA and APAC both delivering mid-single-digit growth. The Americas lagged, impacted by York integration challenges (quality issues now rectified) and a US government shutdown impact in Q3. PFAS now represents approximately 6% of Environmental revenues and is growing well ahead of the broader portfolio.

On acquisitions, Wessling was noted as performing ahead of its initial business case, with the Consulting Engineering business divested in November 2025 as planned. York, by contrast, was acknowledged as underperforming, with an active business reset underway and the longer-term case considered still feasible by management. Within Pharmaceutical, overall revenue declined (1.6%) organically, though Nuvisan’s underlying EBIT grew 123% with margin improving approximately 450 bps following completion of the €25 million transformation programme, delivered ahead of schedule. Andrea Vallejo has commenced as the new EGM Environmental at the start of FY27.

What is TIC and why does ALS’s position in it matter to investors?

Testing, Inspection and Certification (TIC) refers to independent, third-party services that verify quality, safety and compliance across industries including mining, food safety, environmental monitoring, pharmaceuticals and industrial quality assurance. Demand for TIC services is structurally regulation-driven rather than discretionary; companies and governments cannot opt out of mandatory testing requirements, which makes the sector more resilient across economic cycles than many other industrials sub-segments.

ALS operates a hub-and-spoke model within TIC. Central hub laboratories process high sample volumes using specialised, high-throughput equipment, while spoke laboratories positioned closer to clients provide fast sample collection and turnaround. The group currently supports approximately 80 Minerals spoke labs and approximately 135 Environmental spoke labs globally, with 80% of group revenue operating on a unified Laboratory Information Management System (LIMS) platform.

Several structural tailwinds support continued demand growth for ALS’s services. The energy transition is driving investment in critical minerals exploration, expanding the addressable market for Geochemistry and Metallurgy. Rising food safety regulation globally underpins Food testing growth. PFAS contamination monitoring represents an accelerating regulatory imperative. Pharmaceutical outsourcing continues to grow as drug developers and manufacturers seek specialist third-party testing capabilities.

Building the lab of the future — and what FY27 looks like from here

Smart labs, AI, and automation moving from cost to margin lever

The presentation detailed ALS’s “Lab of the Future” initiative, positioning FY26 as an acceleration point in the transition from investment to early returns. With 80% of group revenue on a unified LIMS platform, management described this as one of the largest proprietary datasets in the TIC industry, forming the foundation for AI-driven competitive advantage.

GenAI has been deployed to 22,000 employees at less than the cost of a single full-time employee (FTE). The AI Marketplace went live in April 2026, with over 5,000 active users. On the robotics side, one robot costs approximately $7,000 to build compared to approximately $100,000 per year per FTE, with 20+ robots already in production and a pipeline of 115 opportunities identified. With approximately 60% of the cost base being labour, management framed every automation initiative as a direct margin lever.

The four hub lab upgrade projects remain on track, with $93.7 million spent to date (approximately 40% of the combined budget) and approximately $70 million planned for FY27:

1. Lima, Peru (FY27): $30.2 million spent (49% of budget); commissioning expected September 2026
2. Sydney, Australia (FY27): $26.1 million spent (43% of budget); new warehouse operational May 2026; full site commissioning by March 2027
3. Bangkok, Thailand (FY28): $22.8 million spent (51% of budget); civil construction commenced
4. Prague, Czech Republic (FY30): $14.6 million spent (21% of budget); permitting and architectural studies completed

FY27 guidance — management targets continued growth and margin expansion

Management outlined the following perspectives for FY27:

• Group: mid-to-high single-digit organic revenue growth; margin expansion at a similar rate to FY26 improvement
• Minerals: 13–15% organic revenue growth for FY27; higher confidence in 15–17% for H1 FY27 specifically; H1 margins expected to be maintained at H2 FY26 levels, with a further 30–50 bps incremental improvement targeted in H2 FY27
• Industrial Materials: continued high single-digit organic growth with incremental margin improvement
• Life Sciences: improved mid-single-digit organic revenue growth; incremental margin improvement of 30–50 bps
• Environmental: improved Americas performance expected; EMEA and APAC to continue solid growth
• Nuvisan: further €5 million in annualised savings anticipated in FY27; pipeline conversion into new contract revenues expected
• Supply chain risk: Middle East conflict creates an earnings risk of approximately A$5–10 million at group level, independent of divisional organic growth guidance
• FX: adverse FY27 impact expected; every 1% movement in major currencies versus the AUD equates to an estimated annualised impact of approximately $3 million on underlying EBIT and approximately $2 million on underlying NPAT
• Balance sheet: strong position supports continued hub lab capex and bolt-on M&A optionality

Don’t Miss the Next Industrials Breakout on ASX

Big News Blast delivers FREE breaking ASX news and in-depth analysis straight to your inbox within minutes of release. Join 20,000+ investors already staying ahead of market-moving announcements across Industrials and beyond. Click the “Free Alerts” button to start receiving real-time coverage the moment it hits the ASX.